---
title: "Zhejiang Jingxin Pharmaceutical Co.,Ltd. (002020.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002020.SZ.md"
symbol: "002020.SZ"
name: "Zhejiang Jingxin Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T22:41:42.507Z"
locales:
  - [en](https://longbridge.com/en/quote/002020.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002020.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002020.SZ.md)
---

# Zhejiang Jingxin Pharmaceutical Co.,Ltd. (002020.SZ)

## Company Overview

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.jingxinpharm.com](https://www.jingxinpharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.57)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 95 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.43% |  |
| Net Profit YoY | 7.93% |  |
| P/B Ratio | 2.00 |  |
| Dividend Ratio | 2.33% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12231110120.22 |  |
| Revenue | 4043506237.74 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 51.08% | B |
| Revenue YoY | -0.43% | D |
| Net Profit YoY | 7.93% | C |
| Total Assets YoY | 0.90% | C |
| Net Assets YoY | 7.14% | B |
| Cash Flow Margin | 105.32% | C |
| OCF YoY | -0.43% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 23.90% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Jingxin Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "7.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.33%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12231110120.22",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4043506237.74",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "51.08%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.43%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "7.93%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.90%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "7.14%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "105.32%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-0.43%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.90%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 16.17 | 22/215 | 23.87 | 20.54 | 17.44 |
| PB | 2.02 | 85/215 | 3.01 | 2.59 | 2.19 |
| PS (TTM) | 3.04 | 76/215 | 4.20 | 3.66 | 3.20 |
| Dividend Yield | 2.32% | 55/215 | 2.20% | 1.93% | 1.68% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-06T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.27 |
| Highest Target | 16.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002020.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002020.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002020.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002020.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**